Trial Profile
Genomic Analysis of the Enhanced Response to Heart Failure Therapy in African Americans
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs Hydralazine/isosorbide dinitrate (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms GRAHF-2
- 19 Apr 2023 Status changed from active, no longer recruiting to completed.
- 11 Jan 2022 Planned End Date changed from 1 Aug 2021 to 30 Apr 2022.
- 02 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021.